Yearly Archive

Yearly Archives: 2021

May 24, 2021 no comments

Why Small Beats Big: the Hidden Cost of Too Many Voices

The coronavirus pandemic has taught us a lot of lessons.  But some, such as exactly why small biotech companies are increasingly making all the running in early-stage drug discovery and development, are slightly less obvious than others.

Just this week, we have seen the UK Scientific Advisory Group for Emergencies (SAGE) urge the Government to slow the lifting of restrictions out of concern that the so-called Indian variant of covid might be spreading more quickly and could cause a further wave of infections and possibly therefore hospitalizations and deaths.

What does that have to do with the power of small teams in drug discovery?

The common thread is incentives.  Consider the position of the SAGE group: they are charged with forecasting what might happen to coronarvirus cases in the future, armed with mathematical models whose power largely depends on the assumptions upon which they are based.   Armed with such models, there are certainly scenarios that could see significant challenges for healthcare providers in the future particularly if new variants emerge that current vaccines protect against only weakly.  And all these scenarios are mitigated by caution now.  Keep everyone at home for longer, and the risk of future surge is, undoubtedly, reduced.

Hence the advice offered by the SAGE group to the Government, who are charged with making the decisions as to which restrictions stay in place and which are lifted.

Now consider the same scenario from the perspective of the Government ministers.  Keeping restrictions in place has substantial costs in many different ways: economic costs, impact on mental health, slower and poorer treatment of non-covid illnesses not to mention the strong ethical imperative to avoid restricting liberty except in extremis.  In short, as it has been throughout, the decision what to do has been a fine balancing act between the costs and benefits of restrictions.

Next, look at the impact of the advice from SAGE.  Because of their remit, to look at the best way of reducing the impact of the virus, they have set out the best way, in their view, to achieve that narrow goal.  In many ways, the advice is not all that surprising – at every stage throughout the pandemic more restrictions would have reduced viral spread.  And if there were no other considerations, it would have been the right choice to make.  Arguably, if everyone in the country stayed in complete isolation for a month, the virus would disappear altogether with every transmission chain hitting a brick wall simultaneously.

However, the advice has a more insidious effect.  The bad outcomes they forecast are far from certain.  Indeed it …

More
February 16, 2021 no comments

The history – and the future – of antibody discovery technologies

Monoclonal antibodies are now well-established as a mainstay …

More
January 8, 2021 no comments

Why Sarepta’s most recent failure in DMD was entirely predictable

Yesterday, Sarpeta (NASDAQ: $SRPT) announced that its gene …

More
January 2, 2021 no comments

One dose or two? What the debate about COVID vaccination teaches us about science – and its limitations

Over the past week a furious debate has …

More
November 9, 2020 no comments

The Hidden Superpower of Strategic Focus

The first death unequivocally caused by COVID was reported to …

More
April 14, 2020 no comments

COVID19: Serology is harder than it looks

More than a month after the World Health …

More
January 24, 2018 no comments

The Cult Of DNA-centricity

  Understanding the role of DNA in biology is …

More
October 21, 2014 no comments

D&D On R&D – Lessons For Pharma From The Dungeon Master

The discovery and early development phases of pharmaceutical …

More
April 16, 2014 comments

An open letter to Congressman Waxman on the subject of drug pricing

Dear Congressman Waxman (and anyone else concerned about …

More
April 15, 2014 comments

What Thomas Dimsdale, arguably the world’s first biotech entrepreneur, tells us about drug pricing

Thomas Dimsdale (born in 1712) was arguably the …

More

Yearly Archive